A single-country, multicentre, open-label and non-randomised trial with turoctocog alfa treatment and prophylaxis of bleeding episodes in previously treated patients with moderate or severe Haemophilia A for 8 weeks corresponding to at least 20 EDs.
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms guardian TM 10
- Sponsors Novo Nordisk
- 23 Apr 2019 Status changed from active, no longer recruiting to completed.
- 10 Apr 2019 Planned primary completion date changed from 25 Mar 2019 to 22 Apr 2019.
- 14 Jan 2019 Status changed from recruiting to active, no longer recruiting.